A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

Background: Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition. We report the first Phase 3 placebo‐controlled study of an oral antispasticity agent to use an enriched study design. Methods: A 19‐week follow‐up, multicentre, double‐blind, rando...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	European journal of neurology Ročník 18; číslo 9; s. 1122 - 1131
Hlavní autoři:	Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., Rossi, P., Ambler, Z., Stelmasiak, Z., Erdmann, A., Montalban, X., Klimek, A., Davies, P.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Oxford, UK Blackwell Publishing Ltd 01.09.2011 John Wiley & Sons, Inc
Témata:	Adult Aged Cannabidiol cannabinoids Clinical trials delta-9-tetrahydrocannabinol Double-Blind Method Dronabinol Drug Combinations endocannabinoid system Female Humans Male Middle Aged Multiple sclerosis Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Muscle Spasticity - drug therapy Muscle Spasticity - etiology nabiximols Plant Extracts - therapeutic use Sativex Sleep spasticity
ISSN:	1351-5101, 1468-1331, 1468-1331
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!